<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Transfusion dependence in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) patients may lead to organ damage due to accumulation of non-transferrin-bound iron with consequent increased <z:mp ids='MP_0003674'>oxidative stress</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Iron chelation has been reported in retrospective studies to improve overall survival in low-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, but this information needs to be validated in prospective trials </plain></SENT>
<SENT sid="2" pm="."><plain>The oral iron <z:chebi fb="0" ids="38161">chelator</z:chebi>, <z:chebi fb="0" ids="49005">deferasirox</z:chebi>, has been shown to reduce serum ferritin levels in chelation na√Øve and pre-treated patients and to reduce labile plasma iron, independently from the efficacy on <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="49005">Deferasirox</z:chebi> is a potent NF-kB inhibitor, tested in vivo and on <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cell lines, and this effect may explain in part the phenomenon of hematological improvements reported in case reports and in different clinical trials </plain></SENT>
<SENT sid="4" pm="."><plain>The drug has an acceptable safety profile, with the most common side effects reported being non-progressive change in serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> level, gastrointestinal disturbances, and <z:hpo ids='HP_0000988'>skin rash</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>In this review, we report the results of different studies testing safety and efficacy of <z:chebi fb="0" ids="49005">deferasirox</z:chebi> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, side effects associated with the drug, and suggested management of <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> </plain></SENT>
</text></document>